TY - JOUR
T1 - Theophylline
T2 - Recent advances in the understanding of its mode of action and uses in clinical practice
AU - Vassallo, Robert
AU - Lipsky, James J.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1998
Y1 - 1998
N2 - Theophylline, a drug that has been used for several decades, has several different actions at a cellular level, including inhibition of phosphodiesterase isoenzymes, antagonism of adenosine, enhancement of catecholamine secretion, and modulation of calcium fluxes. Recently, theophylline was found to have several immunomodulatory and anti-inflammatory properties, and thus interest in its use in patients with asthma has been renewed. The use of theophylline in the treatment of asthma and chronic obstructive pulmonary disease has diminished with the advent of new medications, but theophylline remains beneficial, especially in the patient with difficult refractory symptoms. In the future, theophylline may be used as treatment for bradyarrhythmias after cardiac transplantation, prophylactic medication to reduce the severity of nephropathy associated with intravenous administration of contrast material, therapy for breathing problems during sleep, and treatment for leukemias.
AB - Theophylline, a drug that has been used for several decades, has several different actions at a cellular level, including inhibition of phosphodiesterase isoenzymes, antagonism of adenosine, enhancement of catecholamine secretion, and modulation of calcium fluxes. Recently, theophylline was found to have several immunomodulatory and anti-inflammatory properties, and thus interest in its use in patients with asthma has been renewed. The use of theophylline in the treatment of asthma and chronic obstructive pulmonary disease has diminished with the advent of new medications, but theophylline remains beneficial, especially in the patient with difficult refractory symptoms. In the future, theophylline may be used as treatment for bradyarrhythmias after cardiac transplantation, prophylactic medication to reduce the severity of nephropathy associated with intravenous administration of contrast material, therapy for breathing problems during sleep, and treatment for leukemias.
UR - http://www.scopus.com/inward/record.url?scp=0031942519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031942519&partnerID=8YFLogxK
U2 - 10.1016/S0025-6196(11)63701-4
DO - 10.1016/S0025-6196(11)63701-4
M3 - Review article
C2 - 9559039
AN - SCOPUS:0031942519
SN - 0025-6196
VL - 73
SP - 346
EP - 354
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 4
ER -